The Zepbound KwikPen is a four-dose pen. One pen holds a month of weekly doses at one strength, where the original Zepbound pen held a single dose and came four to a box. Lilly prices it below the single-dose pen on its self-pay routes, and searches for it rose sharply through 2026. But the label describes a different product, not just a cheaper box: a different formulation, a step the user performs every week that the old pen did not need, and a clock that runs out on a fixed day whether or not every dose has been used.
This page reads the device from the prescribing information and Instructions for Use (Eli Lilly, DailyMed version effective 28 August 2026) and from FDA's approval letters, all on 3 October 2026. What it costs, by route, is on Zepbound cost; the card terms are on the Zepbound savings card page.
What is in the pen
| Single-dose pen | KwikPen | |
|---|---|---|
| Doses per device | 1 | 4 |
| Volume per dose | 0.5 mL | 0.6 mL |
| Total volume | 0.5 mL | 2.4 mL, plus extra "to allow for device priming" |
| Concentration at the 2.5 mg strength | 5 mg/mL | 4.17 mg/mL |
| Concentration at the 15 mg strength | 30 mg/mL | 25 mg/mL |
| Preservatives | None | Benzyl alcohol 5.4 mg, phenol 1.08 mg per dose (plus glycerin 4.8 mg) |
| Needle | Built in, hidden | Not included — a pen needle is attached each week |
| Priming | None | Before each weekly injection |
| Strengths | Six, one per pen | Six, one per pen |
From the label's sections 3 (dosage forms), 11 (description) and 16 (how supplied), and the carton text.
The same molecule sits in both. What changes is the formulation around it. A single-dose pen is used once and thrown away, so it needs no preservative. A pen that is opened, pierced by four separate needles and kept for up to a month does — the KwikPen's formulation carries the same preservative pair (benzyl alcohol and phenol) as the multi-dose vial, and each dose is a slightly larger, slightly less concentrated volume.
The extra fill is how a four-dose pen can be primed four times. The label says only that the pen "contains additional volume to allow for device priming"; it does not say how much. That extra is the medicine people find left in the pen after the fourth dose, and the Instructions for Use are blunt about it: "Do not inject the leftover medicine. Do not transfer ZEPBOUND from your Pen into a syringe." The pen enforces the limit itself — it "will prevent you from dialing a full dose after you have given yourself 4 weekly doses."
What changes for the person using it
The Instructions for Use describe a weekly routine the single-dose pen does not have: attach a new pen needle, turn the dose knob two clicks to the prime position, release a small amount into the air with the needle pointing up, then dial the full dose until the dose knob stops. Three consequences follow from the label's own text:
- Sight matters. The prescribing information states that the KwikPen "is not recommended for self-administration by those who are visually impaired." The single-dose pen carries no such line.
- Needles are a separate supply. The carton reads "Needles not included". A KwikPen prescription without pen needles cannot be used.
- Never shared. The label adds a warning of its own (section 5.10) — "Never Share a ZEPBOUND KwikPen Between Patients" — because sharing a pen, "even if the pen needle is changed", carries a risk of transmitting blood-borne pathogens.
The label also tells prescribers to make sure patients know which presentation they will receive and to retrain them if it changes. Where on the body the injection goes is the same for every presentation and is covered in how GLP-1 injections are given.
The storage and discard rules
| Single-dose pen | KwikPen, unopened | KwikPen, after first use | |
|---|---|---|---|
| Refrigerator, 36–46°F | Until expiry | Until expiry | Allowed, in the carton |
| Room temperature, up to 86°F | 21 days in total, then discard | 30 days, then discard | Allowed, in the carton |
| Thrown away | After its one dose | — | After 30 days at room temperature, 30 days after first use, or 4 doses — whichever comes first |
| Frozen | Never use | Never use | Never use |
Label section 16.2. Mounjaro's label carries identical figures for its own pens.
The 30-day clock is the rule people miss. It starts at first use, not at the first missed dose. Four weekly doses taken on schedule land on days 0, 7, 14 and 21, which leaves nine days before the pen must be discarded. If the doses drift by more than nine days in total over the month — a delayed week, a holiday — the fourth dose falls after day 30, and the label says the pen goes "even if there is medicine left in it". That is a whole dose's worth of a month's supply. (glp1ledger arithmetic from the label's 30-day and four-dose limits.) What the label says about missed weekly doses in general is on missed GLP-1 dose.
Storage for every GLP-1 brand side by side — pens, syringes and tablets — is on GLP-1 pen storage.
How long FDA took
From application to approval took more than two years.
| Event | Zepbound KwikPen | Mounjaro KwikPen |
|---|---|---|
| Brand approved | 8 November 2023 | 13 May 2022 |
| KwikPen application received | 15 November 2023 | 28 September 2023 |
| FDA complete response letter | 29 January 2025 | 29 January 2025 |
| Lilly's answer | 2 December 2025 | 2 December 2025 |
| KwikPen approved | 20 January 2026 | 20 January 2026 |
| Days from application to approval | 797 | 845 |
FDA approval letters for NDA 217806 supplement 2 and NDA 215866 supplement 9; Drugs@FDA submission history, read 3 October 2026.
Two things in that table are worth reading slowly. The Zepbound application arrived seven days after Zepbound itself was approved, so a multi-dose pen was part of the plan from the start. And both applications received the same complete response on the same day, were answered on the same day and approved on the same day: FDA treated them as one device problem across two brands. The letters do not say what the January 2025 complete response asked for; a complete response letter is not published by FDA, and the approval letters mention it only by date. What the delay was about is not on the public record, and this page does not guess.
The multi-dose vial — the same four-dose formulation without the pen — followed separately, approved on 7 January 2026 (supplement 37, a manufacturing supplement). Both the vial and the KwikPen are what Lilly's lower self-pay prices attach to; the single-dose pen is excluded from them, which Lilly states on its own price pages and which is set out on Zepbound cost.
Where the KwikPen matters for access
- Price. Lilly's self-pay and card tiers name the presentation; the KwikPen and vial carry the lower figures. Dated by dose on Zepbound cost, and the card terms (the KwikPen card allows fewer fills a year than the pen card) on the Zepbound savings card page.
- Medicare. The Medicare GLP-1 Bridge covers Zepbound only as the KwikPen, not the single-dose pen or vials — set out on the Medicare GLP-1 Bridge.
- Where it is filled. Lilly's own channel and its partner pharmacies are described on LillyDirect.
- The diabetes twin. Mounjaro's KwikPen is the same device with the same rules; how the two brands differ is on Mounjaro vs Zepbound.
What this page does not cover
It does not cover dosing or dose changes, which are the prescriber's and are reported on other publications, and it does not cover the molecule itself — Peptide Lexicon's tirzepatide entry does. It reports what the label and FDA's letters state; it is not advice on which presentation to use.
Sources
- Eli Lilly and Company, ZEPBOUND (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use, DailyMed set ID 487cd7e7-434c-4925-99fa-aa80b1cc776b, version effective 2026-08-28 — sections 2.4, 3, 11, 16.1, 16.2, 17 and the KwikPen carton text, dailymed.nlm.nih.gov, read 3 October 2026.
- Eli Lilly and Company, MOUNJARO (tirzepatide) injection, prescribing information, DailyMed set ID d2d7da5d-ad07-4228-955f-cf7e355c8cc0, version effective 2026-08-27 — sections 3, 16.1, 16.2, dailymed.nlm.nih.gov, read 3 October 2026.
- US Food and Drug Administration, supplement approval letter, NDA 217806/S-002 (Zepbound KwikPen), 20 January 2026, accessdata.fda.gov, read 3 October 2026.
- US Food and Drug Administration, supplement approval letter, NDA 215866/S-009 (Mounjaro KwikPen), 20 January 2026, accessdata.fda.gov, read 3 October 2026.
- US Food and Drug Administration, supplement approval letter, NDA 217806/S-037 (multiple-dose vial), 7 January 2026, accessdata.fda.gov, read 3 October 2026.
- US Food and Drug Administration, Drugs@FDA submission history for NDA 217806 and NDA 215866, via open.fda.gov, queried 3 October 2026.